Cemiplimab, an anti-programmed cell death protein-1 monoclonal antibody, has demonstrated clinically meaningful activity with an acceptable safety profile in patients with locally advanced BCC refractory to Hedgehog inhibitor therapy.9 This evidence concerns the gene PDCD1 and skin basal cell carcinoma.